Loading…
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates an EEG portal, which enables real-time remote access to a patient's EEG data. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. CeriBell, Inc. was incorporated in 2014 and is headquartered in Sunnyvale, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $89M | $-50M | $-53M | $-42M | -34.4% | 36.1% | - |
| 2024 | $65M | $-37M | $-40M | $-36M | -21.2% | 44.7% | - |
| 2023 | $45M | $-27M | $-29M | $-30M | 26.2% | 74.5% | - |
| 2022 | $26M | $-35M | $-37M | $-33M | 43.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 25.92 | 45.23 | 65.44 | 89.06 |
| Cost Of Revenue | 4.43 | 7.06 | 8.69 | 10.79 |
| Gross Profit | 21.49 | 38.16 | 56.75 | 78.27 |
| Operating Expense | 57.51 | 68.20 | 96.46 | 136.68 |
| Operating Income | -36.02 | -30.04 | -39.71 | -58.40 |
| EBITDA | -35.06 | -26.51 | -37.32 | -50.18 |
| EBIT | -35.56 | -27.36 | -38.46 | -51.52 |
| Pretax Income | -37.16 | -29.45 | -40.45 | -53.41 |
| Tax Provision | 0 | 0.01 | 0 | 0 |
| Net Income | -37.16 | -29.46 | -40.45 | -53.41 |
| Net Income Common Stockholders | -37.16 | -29.46 | -40.45 | -53.41 |
| Total Expenses | 61.94 | 75.27 | 105.15 | 147.47 |
| Interest Expense | 1.60 | 2.10 | 1.99 | 1.89 |
| Research And Development | 7.24 | 8.99 | 13.56 | 19.14 |
| Selling General And Administration | 50.27 | 59.21 | 82.90 | 117.53 |
| Normalized EBITDA | -34.89 | -26.56 | -35.83 | -50.18 |
| Normalized Income | -36.99 | -29.51 | -38.96 | -53.41 |
| Basic EPS | -1.59 | -1.26 | -3.39 | 0 |
| Diluted EPS | -1.59 | -1.26 | -3.39 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | -0.17 | 0.05 | -1.50 | 0 |
| Total Unusual Items Excluding Goodwill | -0.17 | 0.05 | -1.50 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -37.16 | -29.46 | -40.45 | -53.41 |
| Reconciled Depreciation | 0.50 | 0.85 | 1.14 | 1.34 |
| Reconciled Cost Of Revenue | 4.43 | 7.06 | 8.69 | 10.79 |
| Net Interest Income | -1.60 | -2.10 | -1.99 | -1.89 |
| Net Income From Continuing And Discontinued Operation | -37.16 | -29.46 | -40.45 | -53.41 |
| Total Operating Income As Reported | -36.02 | -30.04 | -39.71 | -58.40 |
| Diluted Average Shares | 23.32 | 23.32 | 11.95 | 0 |
| Basic Average Shares | 23.32 | 23.32 | 11.95 | 0 |
| Diluted NI Availto Com Stockholders | -37.16 | -29.46 | -40.45 | -53.41 |
| Net Income Including Noncontrolling Interests | -37.16 | -29.46 | -40.45 | -53.41 |
| Net Income Continuous Operations | -37.16 | -29.46 | -40.45 | -53.41 |
| Other Income Expense | 0.46 | 2.69 | 1.25 | 6.88 |
| Other Non Operating Income Expenses | 0.64 | 2.64 | 2.74 | 6.88 |
| Gain On Sale Of Security | -0.17 | 0.05 | -1.50 | 0 |
| Net Non Operating Interest Income Expense | -1.60 | -2.10 | -1.99 | -1.89 |
| Interest Expense Non Operating | 1.60 | 2.10 | 1.99 | 1.89 |
| Selling And Marketing Expense | 31.81 | 38.92 | 49.05 | 73.08 |
| General And Administrative Expense | 18.46 | 20.29 | 33.84 | 44.45 |
| Other Gand A | 18.46 | 20.29 | 33.84 | 44.45 |
| Operating Revenue | 25.92 | 45.23 | 65.44 | 89.06 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| CBLLthis co. | CBLL | $729M | - | 4.65 | -34.4% | -10.30 |
| BioAge Labs, Inc. | BIOA | $749M | - | 2.32 | -29.6% | -5.11 |
| Castle Biosciences, Inc. | CSTL | $734M | - | 1.53 | -5.1% | -224.72 |
| Absci Corporation | ABSI | $732M | - | 3.77 | -60.8% | -5.15 |
| Allogene Therapeutics, Inc. | ALLO | $726M | - | 1.65 | -65.3% |
| -1.79 |
| Gyre Therapeutics, Inc. | GYRE | $713M | 367.50 | 6.33 | 3.5% | 46.81 |
| Enhabit, Inc. | EHAB | $704M | - | 1.31 | -0.8% | 13.72 |
| Solid Biosciences Inc. | SLDB | $694M | - | 3.09 | -96.8% | -2.97 |
| Ironwood Pharmaceuticals, Inc. | IRWD | $683M | 27.67 | -2.58 | -9.2% | 8.78 |
| Peer Median | - | 197.58 | 1.99 | -19.4% | -2.38 | |